- Conditions
- Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
- Interventions
- ixazomib citrate, dexamethasone, pomalidomide
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 15,039
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Coronary Artery Disease
- Interventions
- PB127 for injectable suspension
- Drug
- Lead sponsor
- Point Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • San Francisco, California • Stanford, California + 14 more
- Conditions
- Head and Neck Cancer, Lung Cancer, Lymphoma
- Interventions
- Amifostine administered subcutaneously
- Drug
- Lead sponsor
- Mt. Sinai Medical Center, Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Miami Beach, Florida
- Conditions
- Obesity, Hypertension, Hyperlipidemias, Diet Modification
- Interventions
- In-store POP education, Online POP education
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hematologic Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Interventions
- MLN4924
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Buffalo, New York
- Conditions
- Myocardial Infarct
- Interventions
- RNS60, Placebo
- Drug
- Lead sponsor
- Revalesio Corporation
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Pre-Eclampsia, Vascular Diseases
- Interventions
- Omental Biopsy
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis, Cellulitis, Abdominal Aortic Aneurysm, Acute Cholecystitis, Peritoneal Free Fluid, Hydronephrosis, Pleural Effusion, Urinary Retention
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Diseases, Depression
- Interventions
- Psychoeducation; Treatment recommendations, Pharmacotherapy, Usual Care
- Behavioral · Drug · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertension
- Interventions
- Aliskiren, Extended-release metoprolol
- Drug
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sarcoma
- Interventions
- semaxanib
- Drug
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Hemophilia A
- Interventions
- valoctocogene roxaparvovec
- Biological
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 12 more
- Conditions
- Photodamage
- Interventions
- Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .
- Device
- Lead sponsor
- Alma Lasers Inc.
- Industry
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Edina, Minnesota
- Conditions
- Stroke
- Interventions
- Not listed
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Ulcers, Surgical Wound Dehiscence (SWD), Chronic Wounds, Undermined and Tunneling Wounds
- Interventions
- Acellular Porcine-Derived Wound Matrix
- Device
- Lead sponsor
- Reprise Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Coconut Creek, Florida • Tamarac, Florida
- Conditions
- Students, Spinal Cord Injury, Ehlers Danlos Syndrome, Care Givers
- Interventions
- Group Coaching
- Behavioral
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aplastic Anemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Juvenile Myelomonocytic Leukemia, Mastocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenström Macroglobulinemia
- Interventions
- Fludarabine, Busulfan, Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplantation, Peripheral blood stem cell transplantation (PBSCT)
- Drug · Radiation · Biological + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Peripheral Arterial Disease(PAD)
- Interventions
- Not listed
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Hypertension
- Interventions
- Propranolol or Carvedilol, Atenolol, Bisoprolol or Sotalol
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 817,337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- Rivaroxaban, Warfarin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Venous Leg Ulcer
- Interventions
- Cirvo™ Therapy
- Device
- Lead sponsor
- Radial Medical, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Metabolomics, Oxygen Inhalation Therapy
- Interventions
- Oxygen Therapy, Non-rebreather mask
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts